Smart to maintain both focus and budget on making Z more successful in both acute pain & OA. Then, launch T with 2015 budget. That's what I keep hearing, and it makes sense to me. Launching a product is expensive.
Tivorbex will be a failure big time. Side effect profile is bad, real bad. The generic of Tivorbex is bad, most doctors will not write it. I have no idea why Iroko would come out with this product.
